US OptionsDetailed Quotes
INDV250516P10000
- 0.41
- -0.16-28.07%
15min DelayClose Apr 25 16:00 ET
0.44High0.41Low
0.44Open0.57Pre Close6 Volume47 Open Interest10.00Strike Price261.00Turnover100.93%IV17.04%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.41Extrinsic Value100Contract SizeAmericanOptions Type-0.2293Delta0.1112Gamma28.20Leverage Ratio-0.0206Theta-0.0016Rho-6.46Eff Leverage0.0082Vega
Indivior Stock Discussion
Game-Changing OUD Treatment Update: SUBLOCADE Now Offers 1-Hour Start Protocol
Unexpected FDA Delay: Indivior's SUBLOCADE Label Changes Face Setback Despite Clean Review
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.
• Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment providers of the...
No comment yet